Pfizer And Biontech
- All
- News
- Videos
-
'Positive' Trial For Pfizer-BioNTech Covid-Flu Jab
"A pivotal phase three trial evaluating these lead formulations is expected to be initiated in the coming months," they said.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
Moderna Sues Pfizer Over Covid Vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their shot for COVID-19.
-
Pfizer To Seek US Authorisation For 3rd Covid Shot In Children
Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
Pfizer To Seek US Approval For Covid Vaccine For Children Under 5: Report
Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
On Omicron vs Vaccines, New Grounds For Cautious Optimism
The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
BioNTech And Pfizer Expect New Variant Impact Data "Within 2 Weeks"
Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
-
Pfizer Vaccine 100% Effective In Adolescents After 4 Months
Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 percent effective in children 12 to 15 years old, four months after the second dose.
-
Pfizer Requests US Emergency Authorisation For Covid Booster For Adults
Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.
-
'Positive' Trial For Pfizer-BioNTech Covid-Flu Jab
"A pivotal phase three trial evaluating these lead formulations is expected to be initiated in the coming months," they said.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
Moderna Sues Pfizer Over Covid Vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their shot for COVID-19.
-
Pfizer To Seek US Authorisation For 3rd Covid Shot In Children
Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
Pfizer To Seek US Approval For Covid Vaccine For Children Under 5: Report
Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
On Omicron vs Vaccines, New Grounds For Cautious Optimism
The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
BioNTech And Pfizer Expect New Variant Impact Data "Within 2 Weeks"
Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
-
Pfizer Vaccine 100% Effective In Adolescents After 4 Months
Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 percent effective in children 12 to 15 years old, four months after the second dose.
-
Pfizer Requests US Emergency Authorisation For Covid Booster For Adults
Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.
